Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Jul 13, 2023 11:36pm
124 Views
Post# 35540628

RE:RE:RE:Any analyst downgrades

RE:RE:RE:Any analyst downgradesPaul was pretty clear that they wil be more transparent with the restarted trial/ If there is good ionfo coming out of the first few patients, I think we will hear about it in the Fall. IF we don't hear about it, then there is likely cause for some concern.
Trogarzon wrote: Ok thanks... next milestone July 28 to see what happens with Marathon, then august for share issue and consolidation for Nasdaq.. and then what we wait for F8 filing in September and then mid 2024 for cancer data... and then the AGM.. lol. When was the last good surprise we got.. 2018... any deal Paul.. too late for that and too early for that now.  Why should anyone buy a single share of Thera now... why.


<< Previous
Bullboard Posts
Next >>